REPL rose 9.2% after investor alert on FDA concerns
Replimune Group (REPL) rose 9.2% on Aug 6, 2026 after a law firm issued an investor alert tied to an investigation following FDA briefing documents that raised concerns about the company’s data package.
What Replimune announced
Replimune didn’t announce a product milestone or a financing — the headline item was an “investor alert” from Pomerantz Law Firm saying it is investigating claims on behalf of investors.
According to the release, the investigation focuses on whether Replimune and certain officers and/or directors engaged in securities fraud.
The alert points to FDA briefing documents published on July 28, 2026 that discussed Replimune’s submission supporting accelerated approval for RP1 (vusolimogene oderparepvec) combined with Bristol Myers Squibb’s Opdivo in adults with unresectable advanced cutaneous melanoma after progression on a PD-1-blocking therapy.
In those briefing materials, the FDA said the response assessment used in the Phase 1/2 IGNYTE study “confounds interpretation of the reported efficacy results and limits FDA’s ability to verify the reported results.”
What it means for Replimune
An investor alert like this can put a brighter spotlight on regulatory risk at exactly the moment a drug program is trying to clear an FDA pathway like accelerated approval.
The FDA’s stated concern goes straight at the credibility and interpretability of the efficacy readout — a key issue when a company is asking regulators to move quickly based on limited or early-stage data.
If regulators remain unconvinced by the way responses were assessed in IGNYTE, Replimune could face tougher questions about what evidence is needed to support its case for RP1 in this setting.
Separately, the investigation language raises the possibility of legal and reputational overhang, depending on what claims are ultimately pursued.
How the stock reacted
REPL started choppy, then pushed higher through the session.
| Window | Move |
|---|---|
| 5 min | -0.2% |
| 10 min | +2.1% |
| 30 min | +2.9% |
| 1 hour | +2.5% |
| end of day | +9.2% |
On a market-adjusted basis, REPL outperformed the SPY by +9.4% on the day.